IBOGAINE
THAILAND
TREATMENT OVERVIEW
Understanding Ibogaine Treatment
Ibogaine is a naturally occurring alkaloid derived from the root bark of Tabernanthe iboga, a shrub native to Central West Africa. For generations, iboga has been used within Bwiti ceremonial, initiation, and healing traditions.
People explore ibogaine for many reasons, including substance dependence, compulsive patterns, trauma, depression, anxiety, emotional stagnation, and personal or spiritual inquiry.
Ibogaine is best understood as a catalyst rather than a cure. It may bring patterns, memories, and emotional structures into clearer view, creating an opportunity for healing and change.
The lasting value of the experience depends on preparation, setting, and integration.
HOW IBOGAINE WORKS IN THE BODY
A systems-based view of ibogaine
Ibogaine interacts with multiple interconnected systems in the body. These effects are not limited to a single pathway but involve neurological, physiological, and stress-regulation processes.
Click each organ to see how ibogaine reacts
BRAIN
Supports neuroplasticity and behavioural flexibility
NERVOUS SYSTEM
Recalibrates autonomic balance
STRESS RESPONSE
Modulates stress and cortisol systems
HEART
Requires cardiac monitoring and stability
GUT
Influences gut–brain communication
LIVER
Converts ibogaine to noribogaine
KIDNEYS
Supports elimination and hydration balance
Brain
Ibogaine appears to influence multiple neurotransmitter systems involved in learning, mood regulation, and behavioural patterns. Research suggests it may temporarily enhance neuroplasticity, creating a window where established habits and thought patterns can be re-examined. Neurotrophic factors such as BDNF and GDNF are also being studied for their role in supporting neural adaptation and recovery. Together, these processes will contribute to increased cognitive flexibility and emotional insight.
Nervous System
Ibogaine affects both the central and autonomic nervous systems. During the experience, sensory processing and internal awareness often shift, followed by a gradual recalibration period. Some individuals report reduced reactivity and a greater sense of internal steadiness as the nervous system moves toward balance.
Stress Response (HPA Axis)
The body’s stress-response system, often referred to as the HPA axis, regulates cortisol and emotional resilience. Ibogaine may influence this system, potentially interrupting persistent stress patterns and supporting a more regulated response to triggers. This recalibration can contribute to improved emotional regulation over time.
Heart (Cardiac System)
Ibogaine can affect cardiac electrical conduction, which is why screening and monitoring are essential components of responsible practice. Heart rate often slows during the experience, reflecting increased parasympathetic activity. Careful assessment and observation help ensure this system remains stable throughout treatment.
Gut
The gut and brain are closely connected through the gut–brain axis. Ibogaine may temporarily affect appetite and digestion during the acute phase. As emotional processing and stress regulation shift, some individuals notice changes in how the body holds tension and processes internal signals.
Liver
Ibogaine is primarily metabolised in the liver, where it is converted into noribogaine. This metabolite remains active for a longer period and may contribute to sustained mood stabilization and reduced cravings. Healthy liver function supports safe metabolism and clearance.
Kidneys
The kidneys assist in eliminating ibogaine metabolites from the body. Adequate hydration supports this process. Electrolyte balance and fluid intake are therefore important considerations during the recovery phase.
Important
Ibogaine interacts with multiple interconnected systems in the body. These effects are not limited to a single pathway but involve neurological, physiological, and stress-regulation processes.
THE TREATMENT PROCESS
Four phases, one coherent container
The work is structured as a therapeutic process, not a high-volume detox service or a purely ceremonial event. Screening, preparation, treatment, and integration are treated as connected phases.
PHASE 1
The Experience
A test dose is used to assess sensitivity before therapeutic dosing. Dosing is individualized and guided by screening, body weight, medical history, and real-time response.
PHASE 2
Grey Day
The day after treatment, often called the Grey Day, may involve fatigue, mental slowing, emotional sensitivity, and reduced coordination as the body recalibrates.
PHASE 3
The Weeks After
Some people report shifts in clarity, mood, and relationship to compulsive patterns. This is a window of opportunity, not a guaranteed outcome.
Phase 4
Integration
Insights are translated into behaviour, boundaries, habits, and daily decisions. Without integration, old patterns can gradually return.
PHASE 1
The Ibogaine Experience
The process begins with a carefully measured test dose to assess individual sensitivity and physiological response. Once tolerance and safety parameters are confirmed, the therapeutic doses are administered.
Dosing is individualised rather than fixed and is guided by screening results, medical history, body weight, and real-time response.
Throughout the session, vital signs are monitored and established safety protocols remain in place. As ibogaine takes effect, many participants enter a sustained inwardly focused state that may feel dreamlike or visionary. Memories, emotions, and significant life themes may emerge.
Temporary physical effects can include ataxia, or reduced coordination and muscle control, nausea, vomiting, and changes in heart rate. Because ibogaine also carries cardiac and medication-interaction risks, careful screening and monitoring are essential throughout the process.
This phase typically unfolds over many hours and may extend up to 24hours.The intensity gradually builds, reaches a peak, and then subsides as awareness of the body and surroundings returns.
Phase 2
The Integration Day ("Grey Day")
The day following ibogaine administration is commonly referred to as the “Grey Day”.
Physical fatigue, reduced coordination, and mental slowing are common. Sleep may be light or fragmented, and emotional sensitivity can increase. Even when withdrawal symptoms or cravings are reduced, the body may feel temporarily depleted.
This phase reflects the nervous system recalibrating after the acute experience. Support during this time focuses on rest, hydration, electrolyte replenishment, and gentle stabilisation.
Observation continues to ensure both physical and psychological grounding.
Phase 3
In the Weeks that Follow
In the days and weeks after ibogaine, many individuals report shifts in mood, cognitive clarity, and their relationship to established patterns.
Noribogaine, the primary metabolite of ibogaine, remains present in the system for some time and may contribute to reduced inner noise and improved emotional regulation.
This period is often described as a window of opportunity for meaningful change. Changes are not automatic, but the conditions for behavioural and psychological shifts become more accessible.
Physical energy, sleep, and appetite may take time to stabilise. Emotional processing can continue beyond the acute experience, which is why ongoing support remains important.
Phase 4
Integration and Aftercare
Ibogaine can create an opening, but sustained change depends on what follows. Insights, emotional shifts, and behavioural interruptions require structure to become lasting change.
Without integration, there is a natural tendency to return to established patterns.
Integration involves reflection, behavioural adjustment, and the development of new responses in daily life. This may include changes in habits, boundaries, relationships, and decision-making.
The aim is not to hold onto the experience, but to translate it into consistent action over time.